Cat. No.: HY-N0015

Astragalin

(Synonyms: Astragaline; 3-Glucosylkaempferol; Kaempferol 3-β-D-glucopyranoside)

19 Cited Publications

Customer Review

Based on 19 publication(s) in Google Scholar

Astragalin (Astragaline) a flavonoid with anti-inflammatory, antioxidant, anticancer, bacteriostatic activity. Astragalin inhibits cancer cells proliferation and migration, induces apoptosis. Astragalin is orally active and provides nerve and heart protection, and resistance against and osteoporosis.

For research use only. We do not sell to patients.

Purity: 99.94%
CAS No.: 480-10-4
Formula: C₂₁H₂₀O₁₁
Molecular Weight:448.38

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Astragalin Chemical Structure

CAS No.: 480-10-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (19)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

p65

All NF-κB Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>10 μM Compound: 6	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 28165740]
BT-549	IC₅₀	>10 μM Compound: 6	Cytotoxicity against human BT549 cells after 48 hrs by SRB assay Cytotoxicity against human BT549 cells after 48 hrs by SRB assay	[PMID: 28165740]
BV-2	IC₅₀	23.5 μM Compound: 6	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay	[PMID: 28165740]
BV-2	IC₅₀	77.36 μM Compound: 13	Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 23149227]
H9	EC₅₀	80 μg/mL Compound: 4	Inhibitory activity against HIV-1 IIIB replication in H9 cell line Inhibitory activity against HIV-1 IIIB replication in H9 cell line	10.1016/0960-894X(94)80015-4
H9	IC₅₀	<100 μg/mL Compound: 4	Inhibitory activity against H9 cells uninfected with HIV-1 Inhibitory activity against H9 cells uninfected with HIV-1	10.1016/0960-894X(94)80015-4
HCT-15	IC₅₀	23.5 μM Compound: 11	Antiproliferative activity against human HCT15 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human HCT15 cells after 72 hrs by sulforhodamine B assay	[PMID: 25981689]
HL-60	IC₅₀	>50 μg/mL Compound: 4	Antioxidant activity in human HL60 cells assessed as reduction of cytochrome-c release Antioxidant activity in human HL60 cells assessed as reduction of cytochrome-c release	[PMID: 10650074]
Jurkat	IC₅₀	>100 μg/mL Compound: 9	Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay	[PMID: 21546250]
MDCK	CC₅₀	>300 μM Compound: 8	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 19729316]
MDCK	CC₅₀	143.3 μg/mL Compound: 8	Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 15104496]
MDCK	CC₅₀	392.5 μg/mL Compound: 8	Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 15104496]
MDCK	EC₅₀	40 μM Compound: 8	Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect	[PMID: 19729316]
MDCK	EC₅₀	61.9 μM Compound: 8	Antiviral activity against influenza A virus H9N2 A/Chicken/Korea/MS96/96 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against influenza A virus H9N2 A/Chicken/Korea/MS96/96 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect	[PMID: 19729316]
MDCK	EC₅₀	72.8 μM Compound: 8	Inhibition of Influenza A virus A/PR/8/34 (H1N1) neuraminidase activity measured in infected MDCK cells using MUNANA as substrate assessed as fluorescence intensity after 48 hrs Inhibition of Influenza A virus A/PR/8/34 (H1N1) neuraminidase activity measured in infected MDCK cells using MUNANA as substrate assessed as fluorescence intensity after 48 hrs	[PMID: 25927664]
MDCK	IC₅₀	143.3 μg/mL Compound: 8	Cytotoxicity against MDCK cells Cytotoxicity against MDCK cells	[PMID: 15104496]
MDCK	IC₅₀	24.5 μg/mL Compound: 8	Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 15104496]
MDCK	IC₅₀	26.9 μg/mL Compound: 8	Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 15104496]
MDCK	IC₅₀	35.8 μg/mL Compound: 8	Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 15104496]
P388	ED₅₀	8.2 μg/mL Compound: Astragalin	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 3404159]
RAW264.7	IC₅₀	37.1 μM Compound: 21	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis	[PMID: 24679441]
RAW264.7	IC₅₀	40.6 μM Compound: 21	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA	[PMID: 24679441]
RAW264.7	IC₅₀	64 μM Compound: 9	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 21353543]
RAW264.7	IC₅₀	67.1 μM Compound: 9	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs	[PMID: 21353543]
SK-MEL-2	IC₅₀	>10 μM Compound: 6	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 28165740]
SK-OV-3	IC₅₀	>10 μM Compound: 6	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 28165740]
SW-620	IC₅₀	4.6 μM Compound: 11	Antiproliferative activity against human SW620 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human SW620 cells after 72 hrs by sulforhodamine B assay	[PMID: 25981689]
U-251	IC₅₀	37.6 μM Compound: 11	Antiproliferative activity against human U251 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human U251 cells after 72 hrs by sulforhodamine B assay	[PMID: 25981689]
U-87MG ATCC	IC₅₀	3.12 μM Compound: 11	Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay	[PMID: 25981689]
Vero	IC₅₀	174.3 μM Compound: 1	Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by FACS analysis Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by FACS analysis	[PMID: 21466157]

In Vitro

Astragalin (0-80 μg/mL; 24 h, 48 h, 72 h) inhibits cancer cells viability and migration at 20, 40, 80 μM, and shows no cytotoxicity to normal human colon epithelial cell lines NCM460^[1].
Astragalin (80 μg/mL; 4 h, 8 h) interrupts the NF-κB signaling pathway and inhibits NF-κB P65 transcriptional activity in HCT116 cells stimulated by TNF-α^[1].
Astragalin (20, 40, 80 μg/mL; 48 h) induces HCT116 cells apoptosis and arrests cell cycle at G0/G1 phase^[1].
Astragalin (20, 40, 80 μg/mL; 48 h) increases the level of apoptin in HCT116 and decreases the level of anti-apoptotic proteins in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Human colon cancer cell lines (HCT116, LoVo, SW620, SW480, Caco2) and human colon epithelial cell lines NCM460
Concentration:

0, 5, 10, 20, 40, 80 μg/mL
Incubation Time:

24, 48, 72 hours
Result:

Inhibits cancer cells (LoVo, SW620, SW480, Caco2, HCT116) activity at 20, 40, 80 μM.
Inhibited HCT116 cells with IC₅₀s of 121.845, 87.908, 18.883 μg/mL at 24, 48, 72 hours, respectively.
Showed no cytotoxicity with NCM460 cells.

Cell Cycle Analysis^[1]

Cell Line:

Human colon cancer cell HCT116
Concentration:

0, 20, 40, 80 μg/mL
Incubation Time:

48 hours
Result:

Arrested cell cycle at G0/G1.

Western Blot Analysis^[1]

Cell Line:

Human colon cancer cell HCT116
Concentration:

80 μg/mL; pre-treated with 20 ng/mL TNF-α
Incubation Time:

4 or 8 hours
Result:

Increased the expression of pro-apoptotic proteins (caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, P53, and Bax) and decreased the expression of anti-apoptotic proteins (cleaved caspase-3 and Bcl-2) in a dose-dependent manner.

Cell Migration Assay ^[1]

Cell Line:

Human colon cancer cell HCT116
Concentration:

0, 20, 40, 80 μg/mL
Incubation Time:

24, 48, 72 hours
Result:

Reduced release of MMP-2 and MMP-9 enzymes.
Inhibited cell migration with mobilities of 14.38, 13.44, and 5.29% with 20, 40, and 80 μg/mL concentrations, respectively.

In Vivo

Astragalin (25, 50, and 75 mg/kg; p.o.; once every two days; 25 d) reduces the tumor volumes, tumor weight and tumor formation rates and decreases expression of p-NFκB and p-iκκα in nude mouse model with human colon cancer^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male BALB/c nude mice (4-week-old) with HCT116 cells (s.c.)^[1]
Dosage:

0 mg/kg, 25 mg/kg, 50 mg/kg, 75 mg/kg
Administration:

Oral gavage; once every two days; for 25 days
Result:

Resulted tumor inhibition rates of 17.43%, 34.89% (p < 0.01), and 67.06% with 25 mg/kg, 50 mg/kg, 75 mg/kg dose administration.
Showed no effect on mouse weight.

Chemical Information

CAS No. 480-10-4
Appearance Solid
Molecular Weight 448.38
Formula C₂₁H₂₀O₁₁
Color Light yellow to yellow
SMILES

OC1=CC2=C(C(C(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)=C(C4=CC=C(O)C=C4)O2)=O)C(O)=C1
Synonyms

Astragaline; 3-Glucosylkaempferol; Kaempferol 3-β-D-glucopyranoside
Structure Classification
- Flavonoids
- Flavonols
- Phenols
- Polyphenols
Initial Source
- Microorganisms
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (19)

All Cell Proliferation/Viability AssayCell Imaging/StainingApoptosis AnalysisHistological Imaging/StainingWB

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

A pH-Responsive Biomimetic Antioxidant Nanoplatform with Dual Renal Targeting for Synergistic Therapy of Acute Kidney Injury. [Abstract]

2025 Nov 6:e15664. PMID: 41199144
Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Integrated untargeted and targeted metabolomics and microbiome profiling reveal the effects of storage duration on the flavor quality of Rizhao Jinhua white tea. [Abstract]

2025 Oct 24;496(Pt 2):146811. PMID: 41166814
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 May 31:489:144992. PMID: 40466530
Phytomedicine

Protective effects of E Se tea extracts against alcoholic fatty liver disease induced by high fat/alcohol diet: In vivo biological evaluation and molecular docking study. [Abstract]

2022 Jul:101:154113. PMID: 35490493
Food Chem X

Effects of anaerobic treatment on the non-volatile components and angiotensin-converting enzyme (ACE) inhibitory activity of purple-colored leaf tea. [Abstract]

2024 Jul 18:23:101649. PMID: 39139484
Curr Res Food Sci

Natural pigments (anthocyanins and chlorophyll) and antioxidants profiling of European red and green gooseberry (Ribes uva-crispa L.) extracted using green techniques (UAE-citric acid-mediated extraction). [Abstract]

2023 Nov 6:7:100629. PMID: 38034946
Ind Crops Prod

2026 May 8;246:123392.
Ind Crops Prod

2025 Dec 11;239:122458.
Talanta

A targeted strategy for screening bioactive inhibitors from Morus alba L.: Immobilized PTP1B affinity chromatography. [Abstract]

2026 Sep 1:307:129772. PMID: 41955787
Bioresour Bioprocess

Astragalin attenuates caerulein-induced acute pancreatitis by targeting the NLRP3 signaling pathway and gut microbiota. [Abstract]

2025 Dec 3;12(1):139. PMID: 41335362

Astragalin purchased from MedChemExpress. Usage Cited in: Bioresour Bioprocess. 2025 Dec 3;12(1):139. [Abstract]

CCK8 assay of Astragalin (1, 10, 20 μM) on AR42J cells.

Astragalin purchased from MedChemExpress. Usage Cited in: Bioresour Bioprocess. 2025 Dec 3;12(1):139. [Abstract]

Live/dead staining showing living (green) and dying/dead (red) cells treated with Astragalin (10 μM).

Astragalin purchased from MedChemExpress. Usage Cited in: Bioresour Bioprocess. 2025 Dec 3;12(1):139. [Abstract]

Apoptotic rate analyzed by Annexin V-FITC/PI staining and flow cytometry treated with Astragalin (10 μM).

Astragalin purchased from MedChemExpress. Usage Cited in: Bioresour Bioprocess. 2025 Dec 3;12(1):139. [Abstract]

Images of H&E staining in pancreatic tissue treated with Astragalin (50, 75, 100 mg/kg, i.g.).

Astragalin purchased from MedChemExpress. Usage Cited in: Bioresour Bioprocess. 2025 Dec 3;12(1):139. [Abstract]

Western blot of the NLRP3 signaling pathway treated with Astragalin (100 mg/kg, i.g.).
Eur J Pharmacol

Astragalin inhibits hepatitis B virus through functional reconstitution of CD8+ T cells and a direct effect on HBV control. [Abstract]

2025 Aug 29:1005:178108. PMID: 40886877
Int Immunopharmacol

Astragalin mitigates inflammatory osteolysis by negatively modulating osteoclastogenesis via ROS and MAPK signaling pathway. [Abstract]

2022 Nov:112:109278. PMID: 36215870
Cancers (Basel)

Astragalin Attenuates Bone Destruction and the Progression of Bone Metastasis in Breast Cancer. [Abstract]

2025 Oct 27;17(21):3442. PMID: 41228235
Pestic Biochem Physiol

Mechanistic insights into chlorogenic acid and caffeic acid as novel juvenile hormone antagonists. [Abstract]

2025 Dec:215:106655. PMID: 41162045
J Cardiovasc Pharmacol

Astragalin Retards Atherosclerosis by Promoting Cholesterol Efflux and Inhibiting the Inflammatory Response via Upregulating ABCA1 and ABCG1 Expression in Macrophages. [Abstract]

2021 Feb 1;77(2):217-227. PMID: 33165140
Arch Dermatol Res

Astragalin inhibits fibroblast proliferation, motion, and ECM synthesis and regulates the MAPK pathway in keloid. [Abstract]

2025 Mar 19;317(1):599. PMID: 40105997
Cytotechnology

Astragalin inhibits the proliferation of high-risk HPV-positive cervical epithelial cells and attenuates malignant cervical lesions. [Abstract]

2025 Jun;77(3):80. PMID: 40124127
SSRN

2023 Feb 7.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (223.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2303 mL

11.1513 mL

22.3025 mL

5 mM

0.4461 mL

2.2303 mL

4.4605 mL

10 mM

0.2230 mL

1.1151 mL

2.2303 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 1% CMC-Na/saline water

Solubility: 10 mg/mL (22.30 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Yang M, et al. Astragalin Inhibits the Proliferation and Migration of Human Colon Cancer HCT116 Cells by Regulating the NF-κB Signaling Pathway. Front Pharmacol. 2021 Apr 19;12:639256. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2303 mL	11.1513 mL	22.3025 mL	55.7563 mL
	5 mM	0.4461 mL	2.2303 mL	4.4605 mL	11.1513 mL
	10 mM	0.2230 mL	1.1151 mL	2.2303 mL	5.5756 mL
	15 mM	0.1487 mL	0.7434 mL	1.4868 mL	3.7171 mL
	20 mM	0.1115 mL	0.5576 mL	1.1151 mL	2.7878 mL
	25 mM	0.0892 mL	0.4461 mL	0.8921 mL	2.2303 mL
	30 mM	0.0743 mL	0.3717 mL	0.7434 mL	1.8585 mL
	40 mM	0.0558 mL	0.2788 mL	0.5576 mL	1.3939 mL
	50 mM	0.0446 mL	0.2230 mL	0.4461 mL	1.1151 mL
	60 mM	0.0372 mL	0.1859 mL	0.3717 mL	0.9293 mL
	80 mM	0.0279 mL	0.1394 mL	0.2788 mL	0.6970 mL
	100 mM	0.0223 mL	0.1115 mL	0.2230 mL	0.5576 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Astragalin

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Phenols Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Cell Death Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Astragalin

All NF-κB Isoforms

Biological Activity

Chemical Information

Publications (19)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Astragalin Related Classifications

HY-N0015 Related Classifications